Clinical cure and microbiological eradication at test-of-cure clinic visit
| Endpoint | Cure rate |
||
|---|---|---|---|
| Telavancin, n (%) | Vancomycin, n (%) | Difference, % (95%CI) | |
| Clinical cure | |||
| All-treated population | 387/502 (77.1) | 376/510 (73.7) | 3.4 (−1.9, 8.7) |
| Clinically evaluable population | 354/399 (88.7) | 346/395 (87.6) | 1.1 (−3.4, 5.6) |
| Clinically evaluable population (MRSA) | 151/162 (93.2) | 142/163 (87.1) | 6.1 (−0.3, 12.5) |
| Microbiological eradication | |||
| Modified all-treated population | 287/373 (76.9) | 285/38 (74.8) | 2.1 (−4.0, 8.2) |
| Microbiologically evaluable population | 261/290 (90.0) | 249/281 (88.6) | 1.4 (−3.7, 6.5) |
| Microbiologically evaluable population (MRSA) | 149/162 (92.0) | 140/163 (85.9) | 6.1 (−0.7, 12.9) |
| Overall therapeutic response (cure +eradication) | |||
| Modified all-treated population | 281/373 (75.3) | 276/381 (72.4) | 2.9 (−3.4, 9.2) |
| Microbiologically evaluable population | 257/290 (88.6) | 244/281 (86.8) | 1.8 (−3.6, 7.2) |
| Microbiologically evaluable population (MRSA) | 149/162 (92.0) | 138/163 (84.7) | 7.3 (0.4, 14.2) |